Leuprorelin Acetate Injection

The core mechanism of Leuprorelin Acetate Injection in the treatment of endometriosis relies on the optimized pharmacological properties of its acetate group to achieve precise regulation of the hypothalamic-pituitary-gonadal axis, thereby inhibiting the growth and activity of ectopic endometrium. As a GnRH-a drug, its active ingredient leuprorelin acetate has a far higher affinity for pituitary GnRH receptors than endogenous GnRH. Moreover, the acetate dosage form greatly improves drug stability and tissue penetration, enabling slow and sustained release after intramuscular injection and avoiding drastic fluctuations in blood drug concentration.

In the initial stage of administration, the drug briefly stimulates the pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH), leading to a transient increase in ovarian hormone (estrogen, progesterone) levels, a phase known as the "flare-up reaction". However, with continuous administration, the sensitivity of pituitary GnRH receptors is inhibited through negative feedback regulation, resulting in a significant decrease in the pituitary's ability to secrete FSH and LH, and ultimately leading to suppressed ovarian function and a reduction in estrogen levels to postmenopausal levels. The growth of ectopic endometrium is dependent on estrogen support; a low-estrogen environment causes atrophy and degeneration of ectopic endometrial cells, thereby reducing pelvic adhesions and nodule formation, relieving pain symptoms, and achieving therapeutic goals. Compared with other dosage forms, the sustained-release property of the acetate dosage form can maintain a stable hormone-inhibiting effect and avoid symptom recurrence caused by fluctuations in drug concentration.

The application of the product in endometriosis is not limited to a single scenario; instead, it can be adapted to pre-operative adjuvant therapy, post-operative consolidation therapy, conservative therapy and other scenarios according to patients' age, severity of symptoms, fertility needs, etc., providing individualized regimens for patients with different conditions.

For patients with severe symptoms, obvious pelvic adhesions or large ectopic nodules, pre-operative use of it can reduce the volume of ectopic lesions, alleviate pelvic congestion and adhesions, lower surgical difficulty, reduce intra-operative bleeding, and improve the complete resection rate of lesions. It is particularly suitable for patients with large ovarian endometriotic cysts (diameter ≥4cm) complicated with severe pelvic pain. After 2-3 cycles of pre-operative medication, the volume of cysts can be significantly reduced, facilitating surgical operation, while relieving pain and improving patients' physical condition before surgery.

Post-operative consolidation therapy is one of its core application scenarios. The post-operative recurrence rate of endometriosis is relatively high, especially in severe patients, with a 1-year post-operative recurrence rate of up to 20%-40%. Post-operative use of it can further inhibit the activity of residual ectopic endometrial tissue and reduce the risk of recurrence. Clinical guidelines recommend that for patients with moderate to severe endometriosis, 3-6 cycles of GnRH-a therapy should be routinely administered after surgery. Relying on the advantage of long-acting sustained release, it can reduce the frequency of administration (once a month), improve patients' medication compliance, and effectively prolong the recurrence-free period.

In terms of symptom relief, most patients experience significant relief of dysmenorrhea, pelvic pain and other symptoms after 1-2 cycles of medication, with a symptom relief rate of over 80% after 3 cycles. For patients with complicated menstrual disorders, menstruation gradually decreases until amenorrhea after medication with the suppression of ovarian function, and the ectopic endometrium atrophies without hormonal support, controlling pain symptoms from the root cause. In contrast to traditional non-steroidal anti-inflammatory drugs (NSAIDs) that only relieve pain symptomatically, it achieves etiological treatment through regulating the endocrine axis, resulting in more sustained symptom relief with low recurrence rate.

Dosage Form Iteration and Upgrading to Improve Medication Convenience

Dosage form optimization is its core development direction, and the product has now advanced from monthly sustained-release to longer-cycle preparations. The marketing application for the three-month sustained-release leuprorelin microsphere has been submitted, which is expected to be approved in 2026 and will further reduce the frequency of administration. The more groundbreaking 6-month pre-filled injection emulsion has been approved in Europe and the United States for the treatment of prostate cancer, which can be used without mixing and has greatly improved practicality. Domestic Phase III clinical studies for multiple indications are progressing steadily, which is expected to cover the needs of more patients in the future.

Continuous Expansion of Indications to Enrich Clinical Application Scenarios

The existing indications of the drug have covered prostate cancer, endometriosis, etc., with significant potential for future expansion. Clinical research on the indication of central precocious puberty is in progress, and the pediatric patient group will become a new growth highlight. At the same time, research on combination therapy is booming; its combination with dienogest and other drugs for the treatment of post-operative patients with ovarian endometriotic cysts can improve efficacy and reduce recurrence rate, providing a new regimen for complex cases.

Accelerated Global Layout to Strengthen Market Competitiveness

In China, the approval of raw material drug marketing and the implementation of Eurasian Economic Union GMP certification have laid a foundation for preparation production and export. Enterprises are expanding overseas markets by acquiring mature overseas pharmaceutical companies and leveraging their channel and certification advantages, accelerating the global layout. With the expansion of polypeptide raw material drug production capacity and the development of CDMO business, the industrial chain advantages will be further consolidated, the core competitiveness in the global GnRH-a drug market will be strengthened, and patients in more countries and regions will benefit.